ProCE Banner Activity

CAPELLA: Resistance Analysis in Highly Treatment–Experienced Patients Receiving LA Lenacapavir

Slideset Download
Conference Coverage
Through 26 weeks, viral rebound on lenacapavir plus optimized background was associated with a lack of additional active ARVs resulting in functional LEN monotherapy.

Released: November 05, 2021

Expiration: November 04, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp

ViiV Healthcare